THE 5‐YEAR FOLLOW‐UP RESULTS OF THE C5R PROTOCOL WITH RITUXIMAB AND INTRATHECAL LIPOSOMAL CYTARABINE FOR PRIMARY CNS LYMPHOMA: A PROSPECTIVE PHASE 2 STUDY OF THE LYSA. (June 2017) - Ghesquieres, H.; Tilly, H.; Sonet, A.; Dupuis, J.; Nicolas‐Virelizier, E.; Andre, M.; Trullemans, F.; Eisenmann, J.; Delarue, R.; Fleck, E.; Morschhauser, F.; Blay, J.